TransEnterix, Inc. Appoints Eric Smith as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018.

In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence.

“We are very excited to have Eric join the TransEnterix team. He brings a wealth of experience commercializing innovative technologies on a global scale,” said Todd M. Pope, Chief Executive Officer of TransEnterix. “As we look to drive widespread adoption of Senhance, we believe that the addition of Eric’s expertise in developing and driving sales and marketing strategies will complement our existing team as we continue to grow and increase our presence in the United States and around the world.”

Mr. Smith brings over two decades of medical technology experience to TransEnterix, with over a decade of that focused on commercial leadership and marketing strategy. Most recently, he was a Vice President, Franchise Leader Acute Care at KCI Corporation, a developer and manufacturer of wound healing products. While at KCI, he was responsible for the development and commercialization of innovative wound-care technologies on a global scale. Prior to joining KCI, Mr. Smith served as Vice President of Global Strategic Marketing at Cordis Corporation, a developer and manufacturer of medical devices for the treatment of coronary and peripheral vascular diseases. He has also held senior positions at Boston Scientific, C.R. Bard and Ernst & Young. He received his Bachelor’s degree from the University of New Hampshire and his MBA from Babson College.

“I am extremely pleased to be joining TransEnterix during such an exciting time in the company’s history,” said Smith. “Senhance is a transformative technology with a large market opportunity, and I look forward to contributing to the company’s success and improving clinical outcomes and patient care through the use of digital laparoscopy.”

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance™ Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and our current commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Mr. Smith’s expertise in developing and driving sales and marketing strategies will complement TransEnterix’s existing team as TransEnterix continues to group and increase its presence in the United States and around the world and whether Mr. Smith can contribute to TransEnterix’s success and improving clinical outcomes and patient care through the use of digital laparoscopy. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 8, 2018 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.